Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 8, 2012, Pages 806-813

  Ueng, Shir Hwa ^a   Chen, Shin Cheh ^a   Chang, Yu Sun ^b   Hsueh, Swei ^a   Lin, Yung Chang ^a   Chien, Hui Ping ^c   Lo, Yun Feng ^a   Shen, Shih Che ^a   Hsueh, Chuen ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b Graduate Institute of Basic Medical Sciences   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Breast cancer; Phosphorylated mammalian target of rapamycin (p mTOR); triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; MTOR PROTEIN, HUMAN; PROGESTERONE RECEPTOR; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ARTICLE; BREAST TUMOR; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SURVIVAL RATE; TAIWAN;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; PHOSPHORYLATION; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TAIWAN; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84870441216     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Perou C, Sorlie T, Eisen M, Rijn M, Jeffrey S, Rees C, Pollack J, Ross D, Johnsen H, Akslen L, Fluge O, Pergamenschikov A, Williams C, Zhu S, Lonning P, Borresen-Dale A, Brown P and Botstein D. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. Sorlie T. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences 2001; 98: 10869-10874.
3. Sorlie T. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences 2003; 100: 8418-8423.
4. Reis-Filho JS, Westbury C and Pierga JY. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol 2006; 59: 225-231.
5. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D. Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer. Journal of Clinical Oncology 2006; 24: 5652-5657.
6. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clinical Cancer Research 2007; 13: 4429-4434.
7. Reis-Filho JS and Tutt ANJ. Triple negative tumours: a critical review. Histopathology 2007; 52: 108-118.
8. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation 2011; 121: 2750-2767.
9. Umemura S, Yoshida S, Ohta Y, Naito K, Osamura RY and Tokuda Y. Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Science 2007; 98: 1889-1892.
10. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern M-H, Thiery J-P, Hickman JA and Dubois T. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Research 2008; 10: R101.
11. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N and Slamon DJ. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-326.
12. Ma XM and Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10: 307-318.
13. Shaw RJ and Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-430.
14. Cutler NS, Heitman J and Cardenas ME. TOR kinase homologs function in a signal transduction pathway that is conserved from yeast to mammals. Mol Cell Endocrinol 1999; 155: 135-142.
15. Seeliger H, Guba M, Kleespies A, Jauch KW and Bruns CJ. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007; 26: 611-621.
16. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JKV, Markowitz S, Kinzler KW, Vogelstein B and Velculescu VE. High Frequency of Mutations of the PIK3CA Gene in Human Cancers. Science 2004; 304: 554.
17. Perez-Tenorio G, Alkhori L, Olsson B, Waltersson MA, Nordenskjold B, Rutqvist LE, Skoog L and Stal O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007; 13: 3577-3584.
18. Proud CG. Role of mTOR signalling in the control of translation initiation and elongation by nutrients. Curr Top Microbiol Immunol 2004; 279: 215-244.
19. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL and Lichtenstein AK. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004; 279: 2737-2746.
20. Noh WC. Determinants of Rapamycin Sensitivity in Breast Cancer Cells. Clinical Cancer Research 2004; 10: 1013-1023.
21. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P and Gibbons JJ. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249-258.
22. O'Reilly KE. mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt. Cancer Research 2006; 66: 1500-1508.
23. Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefström J, Hautaniemi S and Monni O. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics 2008; 9: 348.
24. Dillon R, White D and Muller W. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007; 26: 1338-1345.
25. Bose S, Chandran S, Mirocha JM and Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 2005; 19: 238-245.
26. Bakarakos P, Theohari I, Nomikos A, Mylona E, Papadimitriou C, Dimopoulos A-M and Nakopoulou L. Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas. Histopathology 2010; 56: 876-882.
27. Walsh S, Flanagan L, Quinn C, Evoy D, McDermott EW, Pierce A and Duffy MJ. mTOR in breast cancer: Differential expression in triplenegative and non-triple-negative tumors. The Breast 2012; 21: 178-182.
28. Nakajima H, Ishikawa Y, Furuya M, Sano T, Ohno Y, Horiguchi J and Oyama T. Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast Cancer 2012; [Epub ahead of print].
29. Elston CW, Ellis IO and Pinder SE. Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 1999; 31: 209-223.
30. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL and Wolff AC. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). Archives of Pathology & Laboratory Medicine 2010; 134: e48-e72.
31. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM and Hayes DF. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Archives of Pathology & Laboratory Medicine 2007; 131: 18-43.
32. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RVP, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS and Greene FL. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. Journal of Clinical Oncology 2002; 20: 3628-3636.
33. Rouzier R. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clinical Cancer Research 2005; 11: 5678-5685.
34. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clinical Cancer Research 2007; 13: 2329-2334.
35. Reis-Filho J and Tutt A. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-118.
36. Zhou X. Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers. Clinical Cancer Research 2004; 10: 6779-6788.
37. Mondesire WH. Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells. Clinical Cancer Research 2004; 10: 7031-7042.
38. Zeng Q, Yang Z, Gao Y-J, Yuan H, Cui K, Shi Y, Wang H, Huang X, Wong STC, Wang Y, Kesari S, Ji R-R and Xu X. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: An in vivo bioluminescence imaging study. European Journal of Cancer 2010; 46: 1132-1143.